| Date | Title | Description |
| 17.07.2026 | Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform | Targets Japan and Singapore as Part of Broader Asia Expansion
TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcas... |
| 12.07.2026 | AstraZeneca's Pipeline Premium Challenged After Wainua Trial Failure | AstraZeneca faced a rare clinical failure with its Wainua drug in a late-stage trial for ATTR cardiomyopathy. Shares plunged significantly, well beyond the drug's estimated financial impact. This event challenges the pharmaceutical giant's ... |
| 11.07.2026 | AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? | AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years.
Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was... |
| 09.07.2026 | AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse | AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition.
Shares slumped and were on track for the worst day in over six years.
Jefferies analysts s... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 03.01.2026 | Ученые из Китая: ИИ будет проектировать РНК-лекарства с нуля за месяцы вместо лет | Группа исследователей из Китая опубликовала в журнале Engineering статью The Future of AI-Driven RNA Drug Development, в которой описала, как искусственный интеллект изменит разработку РНК-лекарств. Авторы — Илинь Янь, Тяньюй У, Хунлинь Ли,... |
| 06.10.2025 | Aerska Secures $21M to Transform Neurological Disease Treatment with RNAi | Dublin-based biotech Aerska raised $21 million in seed financing. This significant capital boost targets groundbreaking RNA interference (RNAi) medicines. The company aims to redefine neurological disease treatment. Aerska employs innovativ... |
| 06.10.2025 | Aerska Raises $21M in Seed Financing | Aerska, a Dublin, Ireland-based biotechnology company improving the treatment of neurological diseases, raised $21M in seed financing.
The round was co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor... |
| 24.09.2025 | Securitas to Spotlight Intelligence-Led Security and Human Expertise at GSX 2025 | Securitas North America
At GSX 2025, Securitas will showcase how intelligence, technology, and the human element intersect to shape the future of protective services through client voices, live panels, and immersive activations.
NEW ORLEANS... |
| 21.08.2025 | Komodo Health Launches Healthcare-Native AI Engine, Marmot | What You Should Know:
– Komodo Health, the leader in AI-powered healthcare intelligence, today launched Marmot™, the first healthcare-native AI engine built to serve as the foundational intelligence layer for the discovery, development, and... |
| 26.06.2025 | DemeRx Appoints Biopharma Industry Veteran Vic Pirotsky to Board of Directors | Pirotsky brings more than two decades of biopharma expertise and a proven track record of leading 8+ successful new drug applications •He advocates for an "Addiction Moonshot" collaboration between government and business •Appoint... |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 08.04.2025 | Merida Biosciences: $121 Million Raised For Creating Therapeutics For Multiple Autoimmune And Allergic Diseases | Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, launched today w... |
| 12.03.2025 | Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline | Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor
Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals
Cambridge, UK, 12 March 2025: Shift Bio... |
| 01.03.2025 | Circio and Moldova: Two Innovators Shaping the Future of Biotechnology and Digital Transformation | In the rapidly evolving landscape of biotechnology and digital innovation, two distinct narratives emerge from Europe: Circio Holding ASA in Norway and the Moldova Digital Summit. Both represent the pulse of progress, each in their own doma... |
| 01.03.2025 | The Future of RNA: Circio's Circular Revolution in Biotechnology | In the world of biotechnology, innovation is the lifeblood. Circio Holding ASA is at the forefront of this revolution. The company is pioneering circular RNA technology, a game-changer in the realm of nucleic acid medicine. This technology ... |
| 26.02.2025 | Circio invited to present advantages of circVec circular RNA technology at international industry conferences | Circio invited to present advantages of circVec circular RNA technology at international industry conferences
Wed, Feb 26, 2025 07:00 CET Report this content
Oslo, Norway 26 February 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology co... |
| 08.01.2025 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report | Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care
LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ... |
| 03.12.2024 | Alucio™ Introduces New AI-Driven Content Assembly Feature in Beacon | Alucio
Supercharging Scientific Exchange
Beacon Further Streamlines the Creation of Custom Presentations to Meet Specific HCP Preferences
SAN FRANCISCO, Dec. 3, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based soft... |
| 22.10.2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 19.09.2024 | 3 Genomics Stocks Transforming Healthcare Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investin... | Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Al... |
| 03.09.2024 | ProofPilot Bolsters Advisory Board with Appointment of Michelle Everill | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- ProofPilot, the leading Clinical Experience Platform (CXP) that centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience, welcomes the addition o... |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam
Will take an active role in expanding partnerships with biopharma
Integrated partnership offering to customers remai... |
| 30.04.2024 | Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including... | The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance
Medison, the creator and leader of the multi-regional partnership category, will utilize its unique... |
| 07.03.2024 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY | - |
| 05.03.2024 | Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when add... | - |
| 26.10.2023 | 米国Alnylam Pharmaceuticals社が9 月6 日に配信: トランスサイレチン型家族性アミロイドポリニューロパチーの患者さんへのホリスティックケアを提唱する提言... | RNAi 治療のリーディングカンパニーであるAlnylam Pharmaceuticals社の日本法人Alnylam Japan株式会社（本社：東京都千代田区、代表取締役社長 岡田 裕、以下「アルナイラム」）は、希少・難治性疾患に対する創薬研究や治療薬の提供とともに、これらの疾患とともに生きる患者さんが少しでもより良い日常生活を送ることができるように、疾患に関する認知・理解の促進、治療に関するサポート、その他に寄与する活動にも取り組んでいます※。
本日は、毎年10月26日に... |
| 09.03.2023 | Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics | ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly inn... |
| 07.02.2023 | CRISPR pioneer Feng Zhang's secretive gene-editing startup has hired ex-Alnylam leaders as CEO and chair | Feng Zhang founded Aera Therapeutics in 2021 based off his gene-editing delivery research. Susan Walsh/AP This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
The gene-editing start... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | After 17 years helping Alnylam steer control of buzzy but unproven science they promised could change medicine, president Barry Greene is leaving the RNAi biotech just as that technology is beginning to hit prime time.
Leaving to “pursue ou... |
| 13.04.2020 | Alnylam To Receive $2 Billion Financing from Blackstone | Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a Cambridge, MA-based RNAi therapeutics company, is to receive an up to $2 billion financing from Blackstone (NYSE: BX).
The package will support Alnylam’s advancement of innovative RNA interfer... |
| 13.04.2020 | Alnylam scores $2B from Blackstone to propel pipeline prospects | With two approved drugs and a third on the way, Alnylam secured some much-needed capital to keep its RNAi pipeline rolling. Blackstone will provide Alnylam with up to $2 billion in exchange for a 50% cut of the royalties on its Novartis-par... |
| 13.04.2020 | Alnylam scores $2B from Blackstone to propel pipeline prospects
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | With two approved drugs and a third on the way, Alnylam secured some much-needed capital to keep its RNAi pipeline rolling. Blackstone will provide Alnylam with up to $2 billion in exchange for a 50% cut of the royalties on its Novartis-par... |
| 10.04.2020 | The coronavirus sneaks into cells through a key receptor. Could targeting it lead to a treatment? | Nearly 20 years ago, when a different coronavirus struck, Michael Farzan and his team figured out how it was getting into human cells: targeting a specific receptor called ACE2 found on certain cells.
During this year’s ongoing novel corona... |
| 04.03.2020 | Alnylam Pharmaceuticals in COVID-19 Partnership with Vir | - |
| 14.02.2015 | Arcturus emerging as a strong player in RNA therapeutics space | The company’s data has advanced to show that this siRNA approach not only works in primates, but has demonstrated longevity in its efficacy. Here’s how Payne describes how it works:
“Imagine a spigot spinning off mutated proteins it’s not s... |
| 03.06.2013 | RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round | “After we finalize licensing agreements and achieve in-vivo proof-of-concept with our IP, then we will be armed with the tools and data necessary to raise substantial money to take us forward to the clinic,” Payne said.
The technique of RNA... |
| 15.11.2010 | Nonprofit takes risk out of device development for Medtronic | For companies like Medtronic Inc. (NYSE:MDT), developing breakthrough technologies to treat untreatable diseases can be expensive and have little promise of financial returns.
The risk is high enough for — even companies as well-resourced a... |
| 12.11.2010 | Medtronic’s research partnership: a roadmap to the future? | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 02.09.2009 | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 23.05.2008 | Lies, Damned Lies, and Statistics: The Definitive Rundown on New England Biotech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
It’s official: 2007 rocked for New England biotech. Whether you look at IPOs, mergers, or venture activity, the region is consistently among the nation’s leaders. And on a per... |
| 12.07.2007 | Roundup: Biogenerics bill in limbo, clashing data on health IT benefits, the RNAi boom, and more | House-Senate confrontation set over biogenerics — Late last month, a key group of senators reached agreement on legislative provisions that would authorize copycat versions of biotech drugs, which are typically complex proteins manufactured... |
| - | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | CINCNNATI, Ohio — Dr. Victor Dzau, the president and CEO of the Duke University Health System, has joined the board of directors of Akebia Therapeutics.
This adds heavyweight talent to some significant fund-raising by Akebia. Last month it ... |
| - | Alnylam sues Moderna & Pfizer, claiming Covid-19 vaccines infringe lipid patent | RNA therapies pioneer Alnylam Pharmaceuticals is suing both Moderna and Pfizer, claiming that their messenger RNA Covid-19 vaccines infringe on a patented technology key to the way these products are delivered in the body and break down wit... |
| - | Arcturus emerging as a strong player in RNA therapeutics space | With a fast-growing pipeline of siRNA and mRNA drugs, San Diego startup Arcturus Therapeutics is poised join the ranks of more established RNA-based drug companies like Alnylam and Moderna Therapeutics.
It’s welcome timing, as the market’s ... |
| - | Medtronic’s research partnership: a roadmap to the future? | For companies like Medtronic Inc. (NYSE:MDT), developing breakthrough technologies to treat untreatable diseases can be risky and expensive. That’s why it’s nice to have a little bit of help from your friends.
Actually, make that a lot of h... |
| - | RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round | An RNAi delivery startup that’s been keeping a low profile has emerged with the announcement of a completed seed funding round and acceptance to Janssen Labs.
MedCity News learned in April that Arcturus Therapeutics was raising a $1.3 milli... |
| - | Alnylam gets $2B funding boost from Blackstone to develop drug pipeline | Alnylam Pharmaceuticals CEO John Maraganore
A large private equity firm is pumping $2 billion into a biotechnology company to help it develop drugs that treat diseases by silencing genes.
Cambridge, Massachusetts-based Alnylam Pharmaceutica... |
